ROLE OF ACA11, AN ORPHAN SMALL NUCLEOLAR RNA IN RESISTANCE TO CANCER CHEMOTHERAPY
孤儿小核仁 RNA ACA11 在抵抗癌症化疗中的作用
基本信息
- 批准号:8477547
- 负责人:
- 金额:$ 31.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-05-01 至 2018-04-30
- 项目状态:已结题
- 来源:
- 关键词:4p16.3AntibodiesB-LymphocytesBindingBiochemicalBiologicalBiological AssayBoxingCell Cycle InhibitionCell DeathCell LineCell NucleolusCell SurvivalCellsChemotherapy-Oncologic ProcedureChromosomal translocationChromosomesChromosomes, Human, Pair 4ClinicalComplementary DNAComplexCustomDataDevelopmentDiagnosisDiseaseEtiologyFunctional RNAGenesGoalsGrantGrowthGuide RNAHealthImmunologic TechniquesIntronsLaboratoriesMalignant NeoplasmsMediator of activation proteinModelingMolecularMorphologyMultiple MyelomaMusNuclear ExtractOncogenesOrphanOxidative StressPatientsPhenotypePlasmaProcessProductionProteinsPublishingRNARNA SplicingReactive Oxygen SpeciesResistanceRibosomal ProteinsRibosomal RNARoleSamplingSmall Nuclear RibonucleoproteinsSmall Nucleolar RNAStressSurvival RateTestingTherapeuticTranscriptTransformed Cell LineWHSC1 genebasebiological adaptation to stresscell growthcell transformationchemotherapeutic agentchemotherapydeep sequencinghistone methyltransferaseknock-downmRNA Expressionmembermutantnew therapeutic targetnoveloverexpressionresearch studyresponsetumorigenesis
项目摘要
DESCRIPTION (provided by applicant): The t(4;14) chromosomal translocation found in 20% of multiple myeloma (MM) cases leads to a shorter survival rate in an already incurable disease. The candidate oncogene overexpressed from the t(4;14) translocation, WHSC1 (MMSET), is unable to transform cells in culture or drive tumorigenesis in mice on its own. Examination of a 2 MB region around the t(4;14) breakpoint revealed the overexpression of a 125 bp orphan H/ACA class non-coding RNA, ACA11, which was confirmed to be up-regulated in t(4;14) MM cell lines and patient samples. Further preliminary studies demonstrate ACA11 localizes to the nucleolus as part of an small nuclear ribonucleoprotein (snRNP) complex. In addition, ACA11 overexpression reduces the levels of reactive oxygen species (ROS) in response to oxidative stress and increases cell survival in the presence of chemotherapeutic agents. We hypothesize that the overexpression of ACA11 in t(4;14) MM reduces ROS-induced cell death leading to the development and/or progression of MM. The ultimate goal of this proposal is to elucidate the mechanism by which ACA11 exerts its inhibitory effects on ROS-induced cell cycle inhibition and cell death in t(4;14) MM cell lines. We hypothesize that the overexpression of the ACA11 snoRNA in t(4;14) MM results in the altered splicing of specific RNA transcripts involved in the cellular response to ROS. These selected transcripts will encode either RNA or proteins critical for B-cell survival in MM. Therefore, ACA11 and its associated snRNP's will be potential novel targets for MM treatment or diagnosis. Three specific aims of the grant are proposed: Aim 1: To test the hypothesis that ACA11 must interact with snRNPs to exert its inhibition of oxidative stress induced cell death Aim 2: To test the hypothesis that ACA11 regulates ROS levels through modulating splicing of snoRNAs from ribosomal protein transcripts Aim 3: To test the hypothesis that overexpression of ACA11 leads to an inhibition of nucleolar stress-induced, p53-regulated ROS production
描述(由申请人提供):在20%的多发性骨髓瘤(MM)病例中发现的t(4;14)染色体易位导致在已经无法治愈的疾病中较短的生存率。t(4;14)易位中过表达的候选癌基因WHSC1 (MMSET)不能在培养中转化细胞,也不能单独在小鼠中驱动肿瘤发生。对t(4;14)断点附近的2mb区域进行检查,发现125 bp的孤儿H/ACA类非编码RNA ACA11过表达,证实在t(4;14) MM细胞系和患者样本中ACA11上调。进一步的初步研究表明,ACA11作为小核核糖核蛋白(snRNP)复合物的一部分定位于核核。此外,ACA11过表达降低氧化应激反应中的活性氧(ROS)水平,并在化疗药物存在下提高细胞存活率。我们假设在t(4;14) MM中ACA11的过表达减少了ros诱导的细胞死亡,从而导致MM的发生和/或进展。本研究的最终目的是阐明ACA11在t(4;14) MM细胞系中发挥其抑制ros诱导的细胞周期抑制和细胞死亡的机制。我们假设在t(4;14) MM中ACA11 snoRNA的过表达导致参与细胞对ROS反应的特定RNA转录物剪接改变。这些选择的转录本将编码对MM中b细胞存活至关重要的RNA或蛋白质。因此,ACA11及其相关snRNP将成为MM治疗或诊断的潜在新靶点。该基金提出了三个具体目的:目的1:验证ACA11必须与snRNPs相互作用以发挥其对氧化应激诱导的细胞死亡的抑制作用的假设;目的2:验证ACA11通过调节核糖体蛋白转录物的snoRNAs剪接来调节ROS水平的假设;目的3:验证ACA11过表达导致核核应激诱导的p53调节的ROS产生的抑制的假设
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MICHAEL H TOMASSON其他文献
MICHAEL H TOMASSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MICHAEL H TOMASSON', 18)}}的其他基金
Sleep Disordered Breathing as a Targetable Risk Factor in Multiple Myeloma
睡眠呼吸障碍作为多发性骨髓瘤的目标危险因素
- 批准号:
10531893 - 财政年份:2021
- 资助金额:
$ 31.54万 - 项目类别:
MOLECULAR TARGETS OF TRANSLOCATION T(4;14) IN MULTIPLE MYELOMA PATHOGENESIS
多发性骨髓瘤发病机制中 T(4;14) 易位的分子靶点
- 批准号:
9187811 - 财政年份:2014
- 资助金额:
$ 31.54万 - 项目类别:
MOLECULAR TARGETS OF TRANSLOCATION T(4;14) IN MULTIPLE MYELOMA PATHOGENESIS
多发性骨髓瘤发病机制中 T(4;14) 易位的分子靶点
- 批准号:
8997472 - 财政年份:2014
- 资助金额:
$ 31.54万 - 项目类别:
MOLECULAR TARGETS OF TRANSLOCATION T(4;14) IN MULTIPLE MYELOMA PATHOGENESIS
多发性骨髓瘤发病机制中 T(4;14) 易位的分子靶点
- 批准号:
8630472 - 财政年份:2014
- 资助金额:
$ 31.54万 - 项目类别:
ROLE OF ACA11, AN ORPHAN SMALL NUCLEOLAR RNA IN RESISTANCE TO CANCER CHEMOTHERAPY
孤儿小核仁 RNA ACA11 在抵抗癌症化疗中的作用
- 批准号:
8656669 - 财政年份:2013
- 资助金额:
$ 31.54万 - 项目类别:
Genomics of AML: Contribution of Cytokine Signaling Pathways to Leukemogenesis
AML 基因组学:细胞因子信号通路对白血病发生的贡献
- 批准号:
8375663 - 财政年份:2012
- 资助金额:
$ 31.54万 - 项目类别:
ENVIRONMENT & GENETICS OF MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE (MGUS)
环境
- 批准号:
8321967 - 财政年份:2011
- 资助金额:
$ 31.54万 - 项目类别:
ENVIRONMENT & GENETICS OF MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE (MGUS)
环境
- 批准号:
8177842 - 财政年份:2011
- 资助金额:
$ 31.54万 - 项目类别:
EXPLORATION OF NEUROBEACHIN (NBEA)'S ROLE IN MULTIPLE MYELOMA
探索 NEUROBEACHIN (NBEA) 在多发性骨髓瘤中的作用
- 批准号:
7708330 - 财政年份:2009
- 资助金额:
$ 31.54万 - 项目类别:
Genomics of AML: Contribution of Cytokine Signaling Pathways to Leukemogenesis
AML 基因组学:细胞因子信号通路对白血病发生的贡献
- 批准号:
7465878 - 财政年份:2008
- 资助金额:
$ 31.54万 - 项目类别:
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 31.54万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 31.54万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 31.54万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 31.54万 - 项目类别:
Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 31.54万 - 项目类别:
Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 31.54万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 31.54万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
- 批准号:
10639161 - 财政年份:2023
- 资助金额:
$ 31.54万 - 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
- 批准号:
10752441 - 财政年份:2023
- 资助金额:
$ 31.54万 - 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
- 批准号:
10867639 - 财政年份:2023
- 资助金额:
$ 31.54万 - 项目类别: